复方鳖甲软肝片联合慢肝解郁胶囊对肝硬化代偿期患者的疗效及安全性观察

目的:探讨复方鳖甲软肝片联合慢肝解郁胶囊治疗代偿期肝硬化的临床疗效及安全性。方法:将100例入住我院的代偿期肝硬化患者按照奇偶数字法随机地均分为对照组与观察组,各为50例。两组均给予保肝抗病毒治疗,观察组在此基础给予复方鳖甲软肝片联合慢肝解郁胶囊治疗。比较两组临床疗效、治疗前后肝功能相关指标变化及不良反应发生情况。结果:(1)对照组临床总有效率为76.00%,显著小于观察组(94.00%)(P<0.05);(2)两组治疗前后临床症状评分差异均具有统计学意义(P<0.05),且两组治疗后临床症状评分差异也具有统计学意义(P<0.05);(3)两组治疗前后肝功能相关指标(AST、ALT、TBil及A/b)差异均具有统计学意义(P<0.05),且两组治疗后上述指标差异也均具有统计学意义(P<0.05);(4)对照组治疗过程中,1例患者HBV DNA转阳后肝功能异常,而观察组无明显副作用。结论:复方鳖甲软肝片联合慢肝解郁胶囊治疗代偿期肝硬化的临床疗效显著,且安全性较高,值得在临床上加以推广及应用。

Observation of the efficacy and safety of Fufangbiejiarangan piece of liver stagnation and slow joint capsule in patients with decompensated cirrhosis

Objective： To investigate the efficacy and safety of Fufangbiejiarangan piece of liver stagnation and slow joint capsule in patients with decompensated cirrhosis. Methods： 100 cases of patients with decompensated cirrhosis in our hospital were randomly divided into a control group and an observation group,and each group was 50 cases. Both groups were given liver antiretroviral therapy,and the observation group were given Fufangbiejiarangan piece of liver stagnation and slow joint capsule treatment on basis of the fundamental treatment. The clinical efficacy,changes in relevant indicators of liver function before and after treatment and the occurrence of adverse reactions were compared. Results：（ 1） The total effective rate of the control group was 76.00%,which was significantly lower than that of the observation group（ 94. 00%）（ P 〈 0. 05）;（ 2） The clinical symptom scores were statistical differences of the two groups between the two groups after treatment（ P 〈0. 05）;（ 3） There were statistical differences of the related indicators of liver function（ AST,ALT,TBil and A / b） of the two groups before and after treatment（ P 〈 0.05 ～ 0. 01）,and after treatment,these indicators were statistically significant differences（ P 〈 0. 05）;（ 4） During treatment,1case of patient＇s HBV DNA transfer after the positive abnormal liver function of the control group,and the observation group had no significant side effects. Conclusion： Fufangbiejiarangan piece of liver stagnation and slow the clinical efficacy of combined treatment of decompensated cirrhosis capsule significant,and high security,it is worth to the promotion and application in clinical practice.